Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV. These diseases cause severe inflammation that can be fatal if not treated. Objective: To test a drug (pacritinib) in people with KSHV-associated KICS or MCD. Eligibility: People aged 18 years and older with KSHV-associated KICS or MCD. They must have at least one symptom. Design: Participants will be screened. They will have a physical exam with blood tests and tests of their heart function. They will have imaging s

Trial Details

NCT ID

NCT06052618

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Sarcoma

Interventions

• Pacritinib

Locations (sample)

• Bethesda, Maryland, United States|38.98067,-77.10026

Key Eligibility Criteria

• Participants must meet KSHV-associated Inflammatory Cytokine Syndrome (KICS) criteria or have histologically or cytologically confirmed Kaposi sarc…
• Age \>= 18 years
• At least one clinical symptom attributed to KSHV-MCD or KICS, as follows:
• Intermittent or persistent fever for at least 1 week (\>38 degrees C)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →